English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

BACKGROUND Glioblastoma (GBM) is a recalcitrant brain cancer in the clinic. The therapeutic effect of using standard care (SC), such as surgery, radiation and/or temozolomide (TMZ) is dismal. CAR T-cell therapy has been increasingly recognized in the field as an innovative therapeutic approach for this malignancy. We identified CD70 as a glioma marker, and show that CD70CAR T cells recognize CD70+ GBMs and mediated regression of established tumors. Since recurrent GBMs that had been heavily treated by the SC treatments expressed a relatively higher level of CD70 than primary tumors, we thus hypothesize that these modalities may help to enhance the expression of CD70 and therapeutic effect of the CD70CAR T cell therapy in GBM. OBJECTIVE To determine if radiation or TMZ treatments could influence the CD70 expression of GBM, and the CD70CAR T-cell recognition. METHODS CD70 expression on GBM cell lines, including primary GBMs (CD70+ or CD70-) and U87 (CD70+), were assessed after treating with escalated doses of irradiation or TMZ. The protein and gene expression were determined by FACS or qRT-PCR analysis, respectively, at 4, 24, 48, and 120 hours post irradiation or TMZ treatment. Tumor recognition post-treatment was also carried out. Paired samples using an RNA-seq dataset from TCGA before and after tumor recurrence were evaluated for the CD70 expression. RESULTS CD70 expression was markedly increased by irradiation or TMZ treatment in a dose-dependent manner (beginning at 24 hours) in vitro in CD70+ GBMs, and a slight increased in the CD70— GBMs. The treatments enhance CD70CAR T cell recognition. Up-regulation of CD70 was found in the paired GBM patients. CONCLUSION This study demonstrates that the irradiation or TMZ treatment significantly up-regulates CD70 expression on GBMs and the CAR-T cell recognition, providing a rationale to combine CD70CAR-T cell therapy with SC for enhanced therapeutic efficacy in GBM.

IMMU-26. RADIATION AND TEMOZOLOMIDE UP-REGULATES CD70 EXPRESSION AND ENHANCES CAR T- CELL RECOGNITION IN GBM